Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported phase II data showing that BI 655066 resulted in nearly double the percentage of patients with moderate to severe plaque psoriasis achieving clear or almost clear skin after 12 weeks of treatment, compared to Stelara (ustekinumab, Johnson & Johnson) (77.1 percent vs. 40 percent).